Replimune Group Inc (REPL)
8.31
-0.66%
Replimune Group Inc (REPL) is currently trading at $8.31. This represents a loss of 0.66% from the previous session. With a market capitalization of $0.69B, REPL is a key component of the Health Care sector. Investors looking to trade REPL should compare margin rates and options platforms to optimize their portfolio management.
Broker Promotion
Get 15 Free Stocks on Moomoo →
T&Cs Apply. Trade REPL commission-free.
Trading Platform Comparison
Moomoo
- Min Deposit: $0
- Commissions: $0
- Fractional Shares: ✅
- Options: ✅
- Notes: Good for small traders
IBKR
- Min Deposit: $0
- Commissions: $0–$0.005/share
- Fractional Shares: ✅
- Options: ✅
- Notes: Professional-level tools
Ameritrade
- Min Deposit: $0
- Commissions: $0
- Fractional Shares: ✅
- Options: ✅
- Notes: Strong research tools
Webull
- Min Deposit: $0
- Commissions: $0
- Fractional Shares: ✅
- Options: ✅
- Notes: Easy mobile app
AI Market Sentiment
As of today, Replimune Group Inc (REPL) shows a bearish trend. Analysts are watching the 8.53 level closely.
Fundamentals
Mkt Cap0.69B
P/E Ratio0.0000
Volume290,303
60-Day Technical Chart
Advanced Charting
Need more indicators for REPL? Use the world's #1 platform.
Open REPL on TradingView →Charting Platforms
TradingView
Advanced charts & indicators, web & mobile
StockCharts
Technical analysis charts with overlays & indicators
BarCharts
Market data, charts, and technical signals
Finviz
Visual stock charts & heatmaps
Yahoo Finance Charts
Basic interactive charts with indicators
Side-by-Side: Stocks Near $8
| Metric |
REPL -0.66% |
MARA +8.70% |
SOUN +4.96% |
QUBT +9.19% |
|---|---|---|---|---|
| Price | $8.31 | $8.77 | $8.78 | $8.86 |
| Mkt Cap | $0.69B | $3.31B | $3.69B | $1.98B |
| - | View → | View → | View → |
Latest Headlines
$REPL stock is up 10% today. Here's what we see in our data.
Quiver Quantitative • Feb 18, 2026
Why Replimune Stock Plummeted by Almost 40% Today
The Motley Fool • Sep 18, 2025
Replimune (REPL) Shares Tank 45% After Company Says No Pathway Identified For Lead Drug RP1, Securities Class Action Pending - Hagens Berman
PR Newswire • Sep 18, 2025
Biotech Replimune's Advanced Melanoma Drug RP1 Faces Uncertain FDA Path Following Critical Meeting
Stock Titan • Sep 18, 2025
REPL Stock Plunges 54% in 3 Months After FDA Rejects Skin Cancer Drug
Yahoo Finance • Sep 24, 2025
● Gemini Agentic AI Analyst Insight for REPL
Market Education
- These Whales are taking all the Ape money - aka Large Fund Mgmt Companies Jul 17, 2023
- From Small Players to Market Movers: How Former Small Caps Are Scaling Up Sep 27, 2025
- Government Shutdowns: What They Mean for Wall Street Sep 26, 2025
External Research